FDAsafety guidance66% confidence
FDA notification regarding unapproved drugs included in kits
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Azurity Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
On September 20, 2024, FDA requested Azurity Pharmaceuticals Inc. stop distributing unapproved drugs marketed as “Unit-of-Use Prescription Compounding Kits.
Supporting Context
- Therapeutic area
- Pharmaceuticals · Compounding
- Sub-indication
- General
Related signal: FDA Orders Azurity Pharmaceuticals to Halt Distribution of Unapproved Compounding Kits